Prevalence, risk factors, and outcomes of gout flare in patients hospitalized for PCR-confirmed COVID-19: A multicenter retrospective cohort study

Faculty of Medicine, Thammasat University, Pathumthani, Thailand; Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand; Department of Rheumatology, Royal Brisbane and Women's Hospital, Metro North Hospital & Health Service; Faculty of Medicine, University of Queensland, Queensland, Australia; Department of Medicine, University of Otago, Wellington, New Zealand. Source of support: The study was supported by clinical research grant from the Faculty of Medicine, Thammasat University, grant number 1-02/2565. Conflict of interest: PR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Kukdong, Novartis, UCB, Roche, Pfizer; meeting attendance support from BMS, Pfizer and UCB and grant funding from Janssen, Novartis, Pfizer and UCB Pharma. RG reports personal fees from AbbVie, Janssen, Cornerstones, Novartis; meeting attendance support from Pfizer. KJ and PS have nothing to disclose. Corresponding author: Kanon Jatuworapruk, Department of Medicine, Faculty of Medicine, Thammasat University, 99/209 Paholyotin Road, Khlong Luang, Pathumthani, 12120 Thailand. Email: kanon@tu.ac.th

Faculty of Medicine, Thammasat University, Pathumthani, Thailand; Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand; Department of Rheumatology, Royal Brisbane and Women's Hospital, Metro North Hospital & Health Service; Faculty of Medicine, University of Queensland, Queensland, Australia; Department of Medicine, University of Otago, Wellington, New Zealand. Source of support: The study was supported by clinical research grant from the Faculty of Medicine, Thammasat University, grant number 1-02/2565. Conflict of interest: PR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Kukdong, Novartis, UCB, Roche, Pfizer; meeting attendance support from BMS, Pfizer and UCB and grant funding from Janssen, Novartis, Pfizer and UCB Pharma. RG reports personal fees from AbbVie, Janssen, Cornerstones, Novartis; meeting attendance support from Pfizer. KJ and PS have nothing to disclose. Corresponding author: Kanon Jatuworapruk, Department of Medicine, Faculty of Medicine, Thammasat University, 99/209 Paholyotin Road, Khlong Luang, Pathumthani, 12120 Thailand. Email: kanon@tu.ac.th

Faculty of Medicine, Thammasat University, Pathumthani, Thailand; Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand; Department of Rheumatology, Royal Brisbane and Women's Hospital, Metro North Hospital & Health Service; Faculty of Medicine, University of Queensland, Queensland, Australia; Department of Medicine, University of Otago, Wellington, New Zealand. Source of support: The study was supported by clinical research grant from the Faculty of Medicine, Thammasat University, grant number 1-02/2565. Conflict of interest: PR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Kukdong, Novartis, UCB, Roche, Pfizer; meeting attendance support from BMS, Pfizer and UCB and grant funding from Janssen, Novartis, Pfizer and UCB Pharma. RG reports personal fees from AbbVie, Janssen, Cornerstones, Novartis; meeting attendance support from Pfizer. KJ and PS have nothing to disclose. Corresponding author: Kanon Jatuworapruk, Department of Medicine, Faculty of Medicine, Thammasat University, 99/209 Paholyotin Road, Khlong Luang, Pathumthani, 12120 Thailand. Email: kanon@tu.ac.th

Faculty of Medicine, Thammasat University, Pathumthani, Thailand; Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand; Department of Rheumatology, Royal Brisbane and Women's Hospital, Metro North Hospital & Health Service; Faculty of Medicine, University of Queensland, Queensland, Australia; Department of Medicine, University of Otago, Wellington, New Zealand. Source of support: The study was supported by clinical research grant from the Faculty of Medicine, Thammasat University, grant number 1-02/2565. Conflict of interest: PR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Kukdong, Novartis, UCB, Roche, Pfizer; meeting attendance support from BMS, Pfizer and UCB and grant funding from Janssen, Novartis, Pfizer and UCB Pharma. RG reports personal fees from AbbVie, Janssen, Cornerstones, Novartis; meeting attendance support from Pfizer. KJ and PS have nothing to disclose. Corresponding author: Kanon Jatuworapruk, Department of Medicine, Faculty of Medicine, Thammasat University, 99/209 Paholyotin Road, Khlong Luang, Pathumthani, 12120 Thailand. Email: kanon@tu.ac.th